### Measure Description
Percentage of non-small cell lung cancer (NSCLC) surgical pathology reports that include anaplastic lymphoma kinase (ALK), epidermal growth factor receptor (EGFR), AND tyrosine protein kinase ROS1 mutation status.

### Denominator Statement
All surgical pathology reports with documentation of lung biopsy or resection that have diagnosis of NSCLC

- **CPT®:** 88305 (Lung, transbronchial biopsy)
- 88307 (Lung, wedge biopsy)
- 88309 (Lung, total/lobe/segment resection)

AND

**ICD-10**

- C34.00: Malignant neoplasm of unspecified main bronchus
- C34.01: Malignant neoplasm of right main bronchus
- C34.02: Malignant neoplasm of left main bronchus
- C34.10: Malignant neoplasm of upper lobe, unspecified bronchus or lung
- C34.11: Malignant neoplasm of upper lobe, right bronchus or lung
- C34.12: Malignant neoplasm of upper lobe, left bronchus or lung
- C34.2: Malignant neoplasm of middle lobe, bronchus or lung
- C34.30: Malignant neoplasm of lower lobe, unspecified bronchus or lung
- C34.31: Malignant neoplasm of lower lobe, right bronchus or lung
- C34.32: Malignant neoplasm of lower lobe, left bronchus or lung
- C34.80: Malignant neoplasm of overlapping sites of unspecified bronchus and lung
- C34.81: Malignant neoplasm of overlapping sites of right bronchus and lung
- C34.82: Malignant neoplasm of overlapping sites of left bronchus and lung
- C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung
- C34.91: Malignant neoplasm of unspecified part of right bronchus or lung
- C34.92: Malignant neoplasm of unspecified part of left bronchus or lung

### Denominator Exclusions
Squamous cell carcinoma

### Denominator Exceptions
Documentation of patient reason(s) biomarker testing was not indicated (eg., patients receiving hospice, patient choice)
<table>
<thead>
<tr>
<th>Numerator Statement</th>
<th>Documentation of system reason(s) biomarker testing was not indicated (e.g. payor-related limitations)</th>
</tr>
</thead>
</table>
| Surgical pathology reports that contain impression or conclusion of, or recommendation for biomarker mutation testing for each of the three biomarkers, ALK, EGFR and ROS1.

Information must be provided about each biomarker; a non-specific note about “biomarker testing” or other documentation that does not conclusively identify each biomarker by name does not meet the measure. The status does NOT have to be the same for all three biomarkers as long as each is recorded. |
| Numerator Exclusions | None |
| Guidance | This measure is to be reported each time a non-small cell lung cancer specimen pathology report is finalized during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

A short note on mutation status can be made in the final report, such as:
- Mutation(s) identified/positive
- No mutation(s) identified/negative
- ALK, EGFR and ROS1 testing previously performed
- ALK, EGFR and ROS1 mutation testing recommended
- ALK, EGFR and ROS1 mutation cannot be determined

Mutation status may be derived from either the primary or a reference laboratory. |
| Measure Information | |
| NQS Domain | Communication and Care Coordination |
| Meaningful Measures Area(s) | Transfer of Health Information and Interoperability |
| Meaningful Measure Rationale | Various gene alterations have been identified as oncogenic drivers for NSCLC, including mutations of EGFR, ALK and ROS1. The Lung Cancer Mutation Consortium found that two thirds of NSCLC patients have an oncogenic driver and that overall survival improves if patients receive matched targeted therapy (1).

Referring physicians depend on both the pathologists’ interpretations of and any recommendations for tests in order to provide quality patient care. If the status is not indicated in each pathology report for the patient, unnecessary repeat testing may be performed delaying treatment and increasing cost. This measure monitors the success of pathologists in effectively communicating...
Knowledge of mutation status of ROS1, ALK and EGFR is thus necessary for appropriate clinical decision-making in advanced NSCLC. Alternative treatments are considered when any one or more of these rearrangements are discovered before or during first-line chemotherapy. ROS1 rearrangement occurs in 1% to 2% of non-small cell lung carcinomas and predicts response to crizotinib and ceritinib therapy, which are first-line treatments. Response rates, including complete responses, approach 70% (2-4). For ALK1, in addition to identifying tumors that are likely to respond to targeted therapies, knowledge of ALK rearrangement status typically predicts inferior response to immunotherapies. Approximately 5% of lung adenocarcinomas have a chromosomal rearrangement involving the ALK gene and associated with ALK protein overexpression. Patients with such tumors respond to therapy with ALK tyrosine kinase inhibitors, such as crizotinib (2, 5). Finally, approximately 20% of lung adenocarcinomas contain an EGFR activating mutation that predicts response to therapy with EGFR tyrosine kinase inhibitors such as erlotinib (2, 6-10).

<table>
<thead>
<tr>
<th>Measure Type</th>
<th>Process</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data Source</td>
<td>Laboratory Information Systems; pathology reports</td>
</tr>
</tbody>
</table>

**Summary of Performance Gap Evidence**

Although ROS1 rearrangement predicts response to first line treatments, testing for ROS1 rearrangements occurs in as few as 20.6% of NSCLC cases (average 27.5%) (1). Testing rates of ALK are higher, but recent study indicated as few as 58-64% of cases were tested for ALK rearrangement (1, 2). Possibly due to the higher rate of EGFR mutation as compared to ROS1 or ALK rearrangement, rates of testing for EGFR mutation are higher than either ROS1 or ALK at approximately 75% (3).

Data regarding testing of all three mutation together are not as widely available, as ROS1 testing in particular has only recently been seen as standard. However, one study from 2019 indicated that 15.4% (875 out of 5688) of NSCLC patients who were tested for biomarkers received multigene panel sequencing (4).

Based on 2019 data in the Pathologists Quality Registry, rates of testing for ALK1 ranged from 28% to 100% with an average performance rate of 76.8%, standard deviation 25 percentage points. Rates of testing for EGFR ranged from 60% to 100% with an average performance rate of 83%, standard deviation 16.1 percentage points. Rates of testing for ROS1 ranged from 17.4% to 100%, with an average performance rate of 65.5%, standard deviation 31.4 percentage points. The three individual biomarker measures show significant performance gaps.

As it was not required that practices report on all three measures, it is not clear how many specimens were tested for all three biomarkers. However there was variability within individual practices; for instance, one practice tested 14 out of 21 samples for ALK, but only tested 4 out of 21 samples for ROS1. It can reasonably be assumed these were the same 21 samples, therefore testing for different biomarkers varies considerably.


<table>
<thead>
<tr>
<th>Measure Owner</th>
<th>College of American Pathologists</th>
</tr>
</thead>
<tbody>
<tr>
<td>NQF ID</td>
<td>N/A</td>
</tr>
<tr>
<td>Number of Performance Rates</td>
<td>1</td>
</tr>
<tr>
<td>Overall Performance Rate</td>
<td>1st Performance Rate</td>
</tr>
<tr>
<td>High-priority</td>
<td>Yes</td>
</tr>
<tr>
<td>Improvement Notation</td>
<td>Inverse Measure: No</td>
</tr>
<tr>
<td></td>
<td>Proportional Measure: Yes (Higher score indicates better quality)</td>
</tr>
<tr>
<td></td>
<td>Continuous Variable Measure: No</td>
</tr>
<tr>
<td></td>
<td>Ratio Measure: No</td>
</tr>
<tr>
<td></td>
<td>Risk-adjusted: No</td>
</tr>
<tr>
<td>Care Setting and Specialty</td>
<td>Care Setting: Other—Laboratories; Telehealth not applicable</td>
</tr>
<tr>
<td></td>
<td>Specialty: Pathology</td>
</tr>
<tr>
<td>Current Clinical Guideline the</td>
<td>ROS1 testing must be performed on all lung advanced-stage adenocarcinoma patients, irrespective of clinical characteristics (Strong Recommendation) (1). The NCCN guideline for non-small cell lung cancer recommends testing for ROS1 rearrangements for nonsquamous NSCLC or NSCLS NOS (Category 2A evidence) (2).</td>
</tr>
<tr>
<td>Measure is Derived From</td>
<td>ALK molecular testing should be used to select patients for ALK-targeted TKI therapy, and patients with lung adenocarcinoma should not be excluded from testing on the basis of clinical characteristics (Grade B evidence) (3). Testing for ALK gene rearrangements and EGFR gene mutations is recommended in the NSCLC algorithm for patients with nonsquamous NSCLC or NSCLC NOS so that patients with these genetic abnormalities can receive effective treatment with targeted agents (Category 1 evidence) (2).</td>
</tr>
<tr>
<td></td>
<td>EGFR molecular testing should be used to select patients for EGFR-targeted TKI therapy, and patients with lung adenocarcinoma should not be excluded from testing on the basis of clinical characteristics (Grade A Evidence) (3).</td>
</tr>
</tbody>
</table>
EGFR mutation testing should be ordered at the time of diagnosis for patients presenting with advanced-stage disease (stage IV according to the 7th edition TNM staging system) who are suitable for therapy or at time of recurrence or progression in patients who originally presented with lower-stage disease but were not previously tested (Grade A Evidence) (3). Physicians may use molecular biomarker testing in tumors with histologies other than adenocarcinoma when clinical features indicate a higher probability of an oncogenic driver (Expert Consensus Opinion) (1, 2).


Measure Flow

**Denominator**

- **Start**
  - Procedure as listed in denominator (CPT 88305, 88307, 88309)
    - Yes: Diagnosis of squamous cell carcinoma
    - No: Initial Population: 100 cases (a)
    - No: Not in Eligible Population/Denominator
      - Denominator Exclusion: 10 cases (x)

- **Diagnosis as listed in denominator (NSCLC)**
  - Yes: Eligible Population/Denominator (90 cases)
  - No: Denominator Exclusion: 10 cases (x)

- **Diagnosis of squamous cell carcinoma**
  - Yes
  - No

**Numerator**

- Surgical pathology report with ALK1, ROS1 and EGFR status documented
  - Yes
  - No

- Documentation of medical reason biomarker status not in pathology report
  - Yes
  - No

- No documentation of testing, reason not given
  - Yes
  - No

- No/Missing Data—Data Completeness Not Met: 10 cases (d)

**SAMPLE CALCULATION:**

\[
\text{Numerator (b=70 reports)} \quad \text{Denominator (a=100 cases)} \quad \text{Denominator Exclusions (x=10 cases)} \quad \text{Denominator Exceptions (c=10 cases)} \quad \frac{70}{100-10-10} = 87.5\%
\]